Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.

Lornoxicam is extensively metabolized by CYP2C9, and a CYP2C9*13 is one of the principal variant alleles in East Asian populations. The aim of this study was to evaluate the effects of CYP2C9*1/*13 on the pharmacokinetic parameters of lornoxicam in healthy individuals. A single oral dose of 8 mg lornoxicam was given to 22 Korean volunteers with different CYP2C9 genotypes (8, 8 and 6 carriers of CYP2C9*1/*1, *1/*3 and *1/*13 genotypes, respectively). Lornoxicam and 5'-hydroxylornoxicam levels were analysed using HPLC-UV in plasma samples collected up to 24 hr after taking the drug. In individuals with CYP2C9*1/*13, lornoxicam had a higher C(max) (p < 0.001), a longer half-life (p < 0.001), a lower oral clearance (p < 0.001) and a higher area under the plasma concentration-time curve from zero to infinity (AUC(inf) ) than in CYP2C9*1/*1 individuals (p < 0.001). The C(max) and AUC(inf) of 5'-hydroxylornoxicam were lower in CYP2C9*1/*13 individuals than in CYP2C9*1/*1 individuals, but the half-life of 5'-hydroxylornoxicam did not differ between the two groups. The half-life, oral clearance and AUC(inf) of lornoxicam were similar in individuals with CYP2C9*1/*13 and those with CYP2C9*1/*3. The C(max) , half-life and AUC(inf) of 5'-hydroxylornoxicam were also similar in both groups, although C(max) was higher in CYP2C9*1/*13 individuals (p < 0.01). A CYP2C9*1/*13 genotype markedly reduced the conversion of lornoxicam to 5'-hydroxylornoxicam, to a similar extent as that observed with the CYP2C9*1/*3 genotype.

[1]  E. García-Martín,et al.  Interethnic and Intraethnic Variability of CYP2C8 and CYP2C9 Polymorphisms in Healthy Individuals , 2012, Molecular Diagnosis & Therapy.

[2]  R. Desnick,et al.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. , 2010, Pharmacogenomics.

[3]  Q. Li,et al.  Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  T. Miyata,et al.  Substrate-Dependent Functional Alterations of Seven CYP2C9 Variants Found in Japanese Subjects , 2009, Drug Metabolism and Disposition.

[5]  H. Zhou,et al.  On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study. , 2006, Biochimie.

[6]  Ya-li Liu,et al.  Effect of the CYP2C9*3 allele on lornoxicam metabolism. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[7]  S. Moriya,et al.  Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. , 2005, Life sciences.

[8]  A. D. Rodrigues,et al.  IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME? , 2005, Drug Metabolism and Disposition.

[9]  C. Jang,et al.  Allele and genotype frequencies of CYP2C9 in a Korean population. , 2005, British journal of clinical pharmacology.

[10]  Yifan Zhang,et al.  ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS , 2005, Drug Metabolism and Disposition.

[11]  Xiaoyan Chen,et al.  Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. , 2005, British journal of clinical pharmacology.

[12]  D. Zhong,et al.  Identification of a novel variant CYP2C9 allele in Chinese. , 2004, Pharmacogenetics.

[13]  P. Bonnabry,et al.  Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam , 2004, European Journal of Clinical Pharmacology.

[14]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[15]  W D Plummer,et al.  Power and sample size calculations for studies involving linear regression. , 1998, Controlled clinical trials.

[16]  N. Davies,et al.  Clinical Pharmacokinetics of Lornoxicam , 1998, Clinical pharmacokinetics.

[17]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.